No Data
No Data
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
Lucid Diagnostics Announces Positive Data From Its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing in a Screening Population
Express News | PAVmed's Veris Health Subsidiary Launches Pilot Program With Ohio State University Comprehensive Cancer Center; First Patients Enrolled In Veris Cancer Care Platform
Express News | PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program With the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Express News | PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $22 From $26
No Data